News and Scientific Presentations

Empirium

Hemab’s scientific legacy in action. Explore our complete collection of presentations and publications documenting our journey to advance understanding of overlooked bleeding disorders.

ISTH 2025: Sutacimig - A Novel Prophylactic Treatment for Glanzmann Thrombasthenia: Interim Analysis of a Phase 1/2 Study

ISTH 2025: Favorable nonclinical safety profile of HMB-002 for prophylactic treatment of Von Willebrand disease

ISTH 2025: VELORA Pioneer - Preliminary safety and PK/PD data of a first-in-human study of HMB-002 in Type 1 Von Willebrand disease

ISTH 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress

WFH 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF) The Potential of HMB-002 as Prophylactic Treatment of von Willebrand Disease (VWD)

WFH 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study

Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease

Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress

EAHAD 2025: Safety and Efficacy of HMB-001 as a Prophylactic Treatment of Glanzmann Thrombasthenia: Interim Analysis of Phase 1/2 Study

EAHAD 2025: Elevating Levels of Endogenous Circulating von Willebrand Factor (VWF): The Potential of HMB-002 as a Prophylactic Treatment of Von Willebrand Disease (VWD)

Hemab Therapeutics Expands Management Team with Appointment of Kate Madigan, MD, as Chief Medical Officer and Announce Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study

Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study

HMB-001 A bispecific antibody accumulating and targeting endogenous fviia to activated platelets enhances thrombin generation and fibrin formation for subcutaneous prophylaxis in Glanzmann Thrombasthenia

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders

EAHAD 2024: Interim Results of the First-in-Human Investigation of HMB-001 for Prophylactic Management of Glanzmann Thrombasthenia

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Bleeding Disorder Programs at the ISTH 2025 Congress

Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease

Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress

Hemab Therapeutics Expands Management Team with Appointment of Kate Madigan, MD, as Chief Medical Officer and Announce Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency

Hemab Therapeutics to Present New Preclinical Data on HMB-001 in Factor VII Deficiency and Initial Findings from Glanzmann Thrombasthenia Natural History Study at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress

Hemab Therapeutics’ Statement Announcing the Planned Departure of Co-Founder and CTO Johan Faber

Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders

Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia

Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress

Hemab Therapeutics Appoints John Maraganore As Chair Of Board Of Directors And Welcomes New Additions To Board And Leadership Team

Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders

Hemab Appoints Mads Behrndt as Chief Financial Officer

Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

Novo Holdings Creates New, Rare Bleeding Disorder Company, Hemab